Colesevelam — Discount Pricing

Other medications in Heart & Cardiovascular

• Colestipol
• Colestipol (Lipid)
• Dapagliflozin (HF)
• Digoxin
• Diltiazem
• Dobutamine
• Dronedarone
• Empagliflozin (HF)

About Colesevelam

Colesevelam is a prescription medication often used to help manage high cholesterol and Type 2 diabetes. If you’ve been prescribed colesevelam, you know the costs can add up. TheDrugClub is here to make managing your health more affordable, offering significant savings on essential medications like colesevelam for our members.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Colesevelam is approved for (FDA label)

Colesevelam hydrochloride is a bile acid sequestrant indicated as an adjunct to diet and exercise to: reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia ( 1.1 ). reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH), unable to reach LDL-C target levels despite an adequate trial of diet and lifestyle modification ( 1.1 ). improve glycemic control in adults with type 2 diabetes mellitus ( 1.2 ). Limitations of Use ( 1.3 ) Do not use for treatment of type 1 diabetes or for diabetic ketoacidosis.

Source: Read the full FDA label on DailyMed. Label effective date: September 27, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Colesevelam (FDA label)

Colesevelam Hydrochloride Tablets, 625 mg are cream to light yellow colored with or without matte appearance, modified capsule shaped, biconvex, film-coated tablets, imprinted '619' on one side and plain on other side. Tablets: 625 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 6a26e745-7e38-4af0-9bcc-566b2812df75. SPL document ID: bf6a10ac-0317-4804-a504-cd00e522dc65. Label effective date: September 27, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Colesevelam (FDA label)

The following important adverse reactions are described below and elsewhere in the labeling: Hypertriglyceridemia and Pancreatitis [see Warnings and Precautions ( 5.1 )] Gastrointestinal Obstruction [see Warnings and Precautions ( 5.2 )] Vitamin K or Fat-Soluble Vitamin Deficiencies [see Warnings and Precautions ( 5.3 )] In clinical trials, the most common (incidence ≥2% and greater than placebo) adverse reactions with colesevelam hydrochloride included constipation, dyspepsia, and nausea ( 6.1 ).

Source: FDA prescribing information (DailyMed). Set ID: 6a26e745-7e38-4af0-9bcc-566b2812df75. SPL document ID: bf6a10ac-0317-4804-a504-cd00e522dc65. Label effective date: September 27, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Colesevelam (FDA label)

Colesevelam hydrochloride is contraindicated in patients with: Serum TG concentrations > 500 mg/dL [see Warnings and Precautions ( 5.1 )] History of hypertriglyceridemia-induced pancreatitis [see Warnings and Precautions ( 5.1 )] A history of bowel obstruction [see Warnings and Precautions ( 5.2 )] Patients with serum triglyceride levels >500 mg/dL ( 4 ). Patients with a history of hypertriglyceridemia-induced pancreatitis ( 4 ). Patients with a history of bowel obstruction ( 4 ).

Source: FDA prescribing information (DailyMed). Set ID: 6a26e745-7e38-4af0-9bcc-566b2812df75. SPL document ID: bf6a10ac-0317-4804-a504-cd00e522dc65. Label effective date: September 27, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Colesevelam (FDA label)

Hypertriglyceridemia and Pancreatitis : Colesevelam hydrochloride can increase TG. Hypertriglyceridemia can cause acute pancreatitis. Monitor lipids, including TG. Instruct patients to discontinue colesevelam hydrochloride and seek prompt medical attention if the symptoms of acute pancreatitis occur ( 5.1 ). Gastrointestinal Obstruction: Cases of bowel obstruction have occurred. Colesevelam hydrochloride is not recommended in patients with gastroparesis, other gastrointestinal motility disorders, and in those who have had major gastrointestinal tract surgery and who may be at risk for bowel obstruction ( 5.2 ). Vitamin K or Fat-Soluble Vitamin Deficiencies: Colesevelam hydrochloride may decrease absorption of fat-soluble vitamins. Patients with a susceptibility to deficiencies of vitamin K (e.g., patients on warfarin, patients with malabsorption syndromes) or other fat-soluble vitamins may be at increased risk. Patients on oral vitamin supplementation should take their vitamins at least 4 hours prior to colesevelam hydrochloride ( 5.3 ).

Source: FDA prescribing information (DailyMed). Set ID: 6a26e745-7e38-4af0-9bcc-566b2812df75. SPL document ID: bf6a10ac-0317-4804-a504-cd00e522dc65. Label effective date: September 27, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Colesevelam (FDA label)

Colesevelam hydrochloride reduces gastrointestinal absorption of some drugs. Administer drugs with a known interaction at least 4 hours prior to colesevelam hydrochloride [see Drug Interactions ( 7 )] . Due to the potential for decreased absorption of other drugs that have not been tested for interaction, especially those with a narrow therapeutic index, consider administering at least 4 hours prior to colesevelam hydrochloride [see Clinical Pharmacology ( 12.3 )] . 7 DRUG INTERACTIONS Concomitant use with colesevelam hydrochloride may decrease the exposure of the following drugs: Drugs with a narrow therapeutic index (e.g., cyclosporine), phenytoin, thyroid hormone replacement therapy, warfarin, oral contraceptives containing ethinyl estradiol and norethindrone, olmesartan medoxomil, and sulfonylureas (glimepiride, glipizide, glyburide). Administer these drugs 4 hours prior to colesevelam hydrochloride. For patients on warfarin, monitor International Normalized Ratio (INR) frequently during initiation then periodically ( 7.1 ).

Source: FDA prescribing information (DailyMed). Set ID: 6a26e745-7e38-4af0-9bcc-566b2812df75. SPL document ID: bf6a10ac-0317-4804-a504-cd00e522dc65. Label effective date: September 27, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.